Ivan Urosev is a distinguished scientist currently working at Roche since July 2024. Urosev previously served as a Postdoctoral Researcher at the University of Zurich from March 2022 to March 2024, where collaboration with industrial partners focused on developing assays and human cellular models for optimizing antibodies to treat amyotrophic lateral sclerosis (ALS). Before this, Urosev was a PhD Research Assistant at the University of Basel from May 2017 to July 2021, contributing to the creation of an engineered protein therapeutic for uncontrolled bleeding, advancing candidates to the preclinical stage. Urosev also has experience as a Research Associate at Accucaps Industries Ltd. in 2016 and as a Graduate Research Assistant at McMaster University from 2014 to 2016, focusing on polymer synthesis for biomedical applications. Urosev holds a PhD in Chemistry from the University of Basel, a MASc in Biomedical Engineering from McMaster University, and a BSc in Biology from Western University.
This person is not in any teams
This person is not in any offices